Neurobiological To Revive Viprinex Stroke Trials Following Empire Acquisition

New Phase III trials for Abbott's former anticoagulant will be based on meta-analyses of previous Phase II and III trials of the pit viper venom-derived agent, Neurobiological Technologies says. Empire licensed Viprinex from Abbott in 2002.